Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation-Reference-Cited by-同舟云学术

Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation

Published:2024-01-06 Issue:3 Volume:204 Page:485-495
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Hardy-Abeloos Camille,Xiao Julie,Oh Cheongeun,Barbee David,Shah Bhartesh,Maisonet Olivier,Perez Carmen,Adams Sylvia,Schnabel Freya,Axelrod Deborah,Guth Amber,Karp Nolan,Cahlon Oren,Gerber Naamit^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10549-023-07190-w.pdf

Reference19 articles.

1. Whelan TJ, Julian JA, Berrang TS et al (2019) External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (rapid): a randomised controlled trial. Lancet 394:2165–2172

2. Meattini I, Marrazzo L, Saieva C et al (2020) Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: Long-term results of the randomized phase iii apbi-imrt-florence trial. J Clin Oncol 38:4175–4183

3. Vicini FA, Cecchini RS, White JR et al (2019) Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 394:2155–2164

4. Coles CE, Griffin CL, Kirby AM et al (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK import low trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390:1048–1060

5. Strnad V, Ott OJ, Hildebrandt G et al (2016) 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 387:229–238